TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04952597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiotherapy
Description: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.~Etoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles~Thoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiotherapy
Description: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.~Etoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles~Thoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)
Study: NCT06106100

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antireflux mucosal ablation
Description: Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed, followed by mucosa markings with straight-fire APC catheter (ERBE Electromedizin, Tübingen, Germany) in forced coagulation mode (VIO300D, ERBE Electromedizin, Tübingen, Germany, 20W). The marking site at 1-cm and 2-cm distal to squamocolumnar junction at anterior-posterior and lesser curvature site, respectively, sparing the greater curvature site of cardia, is done. After marking, mucosal ablation (forced coagulation mode, 1L/min, 80W) is performed at marking site in a hoarse-shoe shape. Adequate ablation depth is defined as reaching the submucosal layer with blackish discolored tissue with carbonization

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed. Using the straight-fire APC catheter to touch the marking sites similar to the treatment group without electrocauterization is performed.
Study: NCT06049498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mongolian Medicine ZhenBao Pills
Description: Mongolian Medicine ZhenBao Pills, orally, 15 pills each time, twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mongolian Medicine ZhenBao Pills Placebo
Description: Mongolian Medicine ZhenBao Pills placebo, orally, 15 pills each time, twice a day.
Study: NCT04745754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embedded primary care in cancer survivorship model
Description: Primacy care physicians will receive comprehensive training in cancer survivorship care for low-risk, early stage breast and colorectal patients. Training will include continuing medical education (CME) modules, webinars, and in-person discussion and clinical shadowing.
Study: NCT05458492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus, tablets 2 mg/day with dose adjustment of 1 to 3 mg/day for residual concentrations between 4 and 10 ng/mL~1 dose daily for 16 weeks
Study: NCT04952597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiotherapy
Description: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.~Etoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles~Thoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)
Study: NCT05563311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise on High-intensity interval training
Description: 3 times a week, for 8 weeks
Study: NCT05614258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG206
Description: All participants in this study will receive the study drug ADG206 in one of the designed dosage level. ADG206 will be administered by intravenous infusion over 60-90 minutes on Day 1 of each treatment cycle until disease progression, intolerable toxicities or withdrawal of consent, or up to 2 years.
Study: NCT06032104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dry beans
Description: 0.5 cup of Bush's Best Cannellini Beans, three times per day before meals blended into a smoothie. If interested and depending on tolerance, participants will also have the opportunity to gradually increase the bean smoothie to a maximum of 1 cup three times per day before meals during the last week of the two-week bean smoothie intervention. If patient cannot not tolerate 1.5 cup of canned cannellini bean, we will reduce per tolerance or offer the option of choosing a bean-based flour (100 gram/day, 23% fiber from Archer Daniels Midland)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dry beans
Description: 0.5 cup of Bush's Best Cannellini Beans, three times per day before meals blended into a smoothie. If interested and depending on tolerance, participants will also have the opportunity to gradually increase the bean smoothie to a maximum of 1 cup three times per day before meals during the last week of the two-week bean smoothie intervention. If patient cannot not tolerate 1.5 cup of canned cannellini bean, we will reduce per tolerance or offer the option of choosing a bean-based flour (100 gram/day, 23% fiber from Archer Daniels Midland)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Usual diet
Description: Usual diet without adding the bean smoothie

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Usual diet
Description: Usual diet without adding the bean smoothie
Study: NCT04707118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin+Nab-paclitaxel+GEM
Description: Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel+GEM
Description: Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles
Study: NCT04314375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Budesonide
Description: 3 milligrams once daily for ages 5 to 11 years 11 months. 6 milligrams once daily for ages 12 to 17 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Budesonide
Description: 6 milligrams once daily for ages 5 to 11 years 11 months. 9 milligrams once daily for ages 12 to 17 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo once daily.
Study: NCT06652750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Management
Description: Conducting routine in-office follow-up for CIED paitents

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5G Cloud Follow-up
Description: This study employed a 5G-cloud follow-up platform, a research tool that allows a device specialist to test, and program CIEDs in real-time from a remote location via an internet connection or mobile wireless network. Consistent with of the 5G remote support terminal externally connected to the programmer, a PAD was installed with a 5G-cloud follow-up app. The onsite medical staff began the cloud follow-up session by contacting the remote device specialist via video call. The connection to the CIED was made by the medical staff through the use of a standard programmer. He was in charge of turning on the programmer and applying the programmer wand to the patient's device. After an initial introduction, communication was established and continued via the wand connection. The remote device specialist logged into the 5G-cloud follow-up app with two-step verification. The remote device specialist then had complete control of the programmer to check and reprogram the device as needed.
Study: NCT05749874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine plus lifestyle intervention
Description: berberine hydrochloride 500mg twice a day plus lifestyle intervention. Lifestyle intervention is based onChinese guideline on the primary prevention of cardiovascular diseases and Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition), including health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus lifestyle intervention
Description: Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention. Lifestyle intervention is based onChinese guideline on the primary prevention of cardiovascular diseases and Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition), including health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc.
Study: NCT05847387

Intervention type: DIAGNOSTIC_TEST
Intervention: V-Check
Description: Preoperative analysis of endothelial tissue staining with vital dye (Trypan Blue 0.05%) and image analysis to identify the percentage of Trypan Blue Positive Areas, corresponding to dead endothelial cells and/or denuded areas of endothelium, in tissues destined to keratoplasty
Study: NCT06106685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose washed microbiota suspension
Description: The high-dose group will be administered a high dose of washed microbiota suspension。
Study: NCT05722483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Intensive Outpatient Program
Description: Components of the intervention include a cognitive behavioral therapy for alcohol use disorder group (12 sessions), a DBT skills group (12 sessions), a Health and Wellness group (8 sessions), weekly individual therapy, weekly medication management appointments, and abstinence monitoring multiple times per day using breathalyzers equipped with facial recognition and internet connectivity.
Study: NCT06106685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose washed microbiota suspension
Description: The low-dose group will be administered a low dose of washed microbiota suspension.
Study: NCT06239454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interleaving stimulation
Description: ILS consists of two rapid and alternate stimulation programs with different contacts, amplitudes, and pulse width but the same frequency up to a maximum of 125Hz. Contact selection is determined by postoperative stereotactic computed tomography and clinical evaluation to achieve a balance between motor improvement and tolerable side effects. For example, ILS is successfully applied for PD motor symptoms (stimulation of subthalamic nucleus) as well as dyskinesia (additional stimulation of zona incerta).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: empirical stimulation
Description: Patients are settled with simple polar stimulation with combined parameters adjustment (monopolar mode, 60\~90µs pulse width, 130\~185Hz frequency and varied voltage) during the follow-up.
Study: NCT05740397

Intervention type: OTHER
Group type: OTHER
Intervention: Management of mean arterial pressure during cardiopulmonary by-pass in cardiac surgery interventions. The MAP will be mantained in the range of values of each study arm
Description: The patients enrolled to elective cardiac surgeries will be evaluated during a pre-operative outpatient visit and widely informed about the chance to participate in the study. When patients undergo to the elective surgery general anaesthesia is administered and CPB is installed. The nominal flow for each patient will be 2,4 l/min/m2.~To keep the MAP values around those corresponding to the randomized group, vasodilator (if MAP overcomes the assigned MAP value) or vasoconstrictor drugs will be used (if MAP value is lower than the assigned group). The following drugs will be used: nitroglicerine at incremental dose of 0,01 mcg/kg/min for a vasodilator effect and norepinephrine at incremental dose of 0,01 mcg/kg/min for a vasoconstrictor effect

Intervention type: OTHER
Group type: OTHER
Intervention: Management of mean arterial pressure during cardiopulmonary by-pass in cardiac surgery interventions. The MAP will be mantained in the range of values of each study arm
Description: The patients enrolled to elective cardiac surgeries will be evaluated during a pre-operative outpatient visit and widely informed about the chance to participate in the study. When patients undergo to the elective surgery general anaesthesia is administered and CPB is installed. The nominal flow for each patient will be 2,4 l/min/m2.~To keep the MAP values around those corresponding to the randomized group, vasodilator (if MAP overcomes the assigned MAP value) or vasoconstrictor drugs will be used (if MAP value is lower than the assigned group). The following drugs will be used: nitroglicerine at incremental dose of 0,01 mcg/kg/min for a vasodilator effect and norepinephrine at incremental dose of 0,01 mcg/kg/min for a vasoconstrictor effect

Intervention type: OTHER
Group type: OTHER
Intervention: Management of mean arterial pressure during cardiopulmonary by-pass in cardiac surgery interventions. The MAP will be mantained in the range of values of each study arm
Description: The patients enrolled to elective cardiac surgeries will be evaluated during a pre-operative outpatient visit and widely informed about the chance to participate in the study. When patients undergo to the elective surgery general anaesthesia is administered and CPB is installed. The nominal flow for each patient will be 2,4 l/min/m2.~To keep the MAP values around those corresponding to the randomized group, vasodilator (if MAP overcomes the assigned MAP value) or vasoconstrictor drugs will be used (if MAP value is lower than the assigned group). The following drugs will be used: nitroglicerine at incremental dose of 0,01 mcg/kg/min for a vasodilator effect and norepinephrine at incremental dose of 0,01 mcg/kg/min for a vasoconstrictor effect
Study: NCT06106685

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will be given equal volume placebo (120ml carrier solution matching the volume of WMT-001), which contains 10% sterile glycerol and saline injection. The drug was administered once a day for 4 days.
Study: NCT05613491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: Put insulin injection into nasal special drug delivery device.Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal saline
Description: Put 0.9% sodium chloride into nasal special drug delivery device.Before anesthesia induction, give the first equal volume saline nasal spray, once per hour, 20 IU each time, until the end of the operation
Study: NCT05064943

Intervention type: DIAGNOSTIC_TEST
Intervention: 2-minute step test
Description: The participant stands and counts for 2 minutes. The minimum height to raise the knee is determined for each participant by calculating the midpoint between the patella and the anterior superior iliac spine. They are instructed to complete as many steps as possible during the 2-minute period. A verbal command is given every 30 seconds to encourage performance: You're doing great, keep it up. If the claudication symptom becomes unbearable, the patient can stop during the test, but the time is not stopped. Patients who discontinue testing due to symptoms of claudication are encouraged to return to testing as soon as possible. An evaluator records the number of steps in the right leg.
Study: NCT05283785

Intervention type: PROCEDURE
Intervention: End To End or End to side sutures
Description: End to end or End to side sutures of ulnar nerve by nerve to quadratus muscle ( branch of anterior interosseous nerve )

Intervention type: PROCEDURE
Intervention: End To End or End to side sutures
Description: End to end or End to side sutures of ulnar nerve by nerve to quadratus muscle ( branch of anterior interosseous nerve )
Study: NCT06141889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaprag
Description: oral, apelin receptor (APJ) agonist
Study: NCT05143736

Intervention type: DIAGNOSTIC_TEST
Intervention: gut and nasal microbiota detection
Description: The nasal and fecal specimens will be collected by swabs from subjects with sepsis. After that, total DNA of nasal and gut microbiota will be extracted , amplified, and sequenced to determine the gut and nasal microbiota.

Intervention type: DIAGNOSTIC_TEST
Intervention: gut and nasal microbiota detection
Description: The nasal and fecal specimens will be collected by swabs from subjects with sepsis. After that, total DNA of nasal and gut microbiota will be extracted , amplified, and sequenced to determine the gut and nasal microbiota.
Study: NCT04956276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered as an SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered as an SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered as an SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an SC infusion.
Study: NCT05398159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trim II
Description: Eligible subjects will receive 3 bi-weekly treatments (once in 2 weeks) with Trim II hands-free applicator belt according to the study protocol.~Trim II hands-free applicator composed of 4 units applied to the abdominal area, using a single-use belt.~Each treatment duration will be 45-60 minutes. Study duration for each subject is approximately 6 months (including screening, 3 treatments and 2 follow-up visits at 1 and 3 months post last treatment).
Study: NCT06605391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiving While Black-LIVE
Description: Caregiving while Black-LIVE is a psychoeducation program that aims to intensify the development of caregiver mastery by integrating the online learning assets of the fully asynchronous Caregiving while Black program with synchronous, group-based opportunities for interactivity and active learning. The Caregiving while Black course includes topics of navigating the healthcare system, managing home life, and caregiver self-care. Once enrolled in the course, participants will be provided instructions for accessing the weekly sessions and course online, and supplemental course materials will be mailed to them. The Canvas platform enables the research team to monitor each individual's movement in the cohort through the asynchronous part of the course. Nudges and reminders to view these materials are sent twice a week via text or email with participant's consent. Synchronous sessions are conducted on a videoconferencing platform.
Study: NCT04866641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-1201 Injection 100 mg Kit
Description: T-1201 Injection 100 mg Kit contains lyophilized powder with a sterile aqueous solution formulated for intravenous administration.
Study: NCT06597279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based dialysis decision support tool
Description: The intervention in this study is the Kidney Care Roadmap, a web-based dialysis decision support tool designed to assist patients with advanced chronic kidney disease and their caregivers.
Study: NCT05356676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometrics
Description: Isometric neck extension -individuals will be taught to place their dominant hand posterior to their head at occiput. Then, they will be told to firmly push the head backwards against that hand, and hold for five seconds and repeat 5 times. • Participants will be asked to place the right hand flat on the same side of the head. Next.~they will be instructed to firmly push the head against right hand and hold for 5 seconds and repeat five times. Same exercise will be repeated with the left hand against the left side of the head as well.~• Participants will be taught to place their right hand on their right cheek. Then, they will be told to rum the face against the right hand and wait for 5 seconds and repeat five times. Same exercise was repeated with the left hand on the left cheek as well.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Therapy
Description: 1. In supine position, the patient will be instructed to take a deep breath in order to relax the body whilst holding his/her shoulders and neck in a comfortable posture.~2. the patient will bend his/her knees and place their feet flat on the floor, and will hold the posture without any other neck movement. Then the patient will be asked to raise their dominant arm to 90° shoulder flexion along with full elbow extension and scapular protraction.~   This posture will be held for 10 seconds before returning to the prior position with 3 laps, 10 repetitions with a one-minute break between.~3. in quadruped position, the patient will lift up their arms alternatively with shoulder abduction and 120 ° flexion. This posture will be held for 10 seconds before returning to the starting position for three laps, 10 repetitions with a 30-second break in between. Participants will be instructed to perform these for 3 times a week for 4 weeks.
Study: NCT06609187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-077
Description: Administration by intravenous infusion for a cycle of 3 weeks.